Anecdotal evidence that ongoing direct oral anticoagulant (DOAC) use might reduce a patient’s risk for severe disease with COVID-19 appears to have been wishful thinking, if the results of a study just published in the Journal of Internal Medicine are any indication. The authors found no association between DOAC use and lower incidence of hospital admission for COVID-19, or a composite of intensive care unit admission of death. As such, they concluded that DOAC use does not change the prognosis for patients with COVID-19. The study reflects analysis of 103,703 patients with nonvalvular atrial fibrillation, 36,875 who had AFib but were not DOAC users, and 355,699 with cardiovascular disease who were not DOAC users.
Update: Study Finds No Evidence That DOAC Use Reduces Risk for Severe COVID-19